[{"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "XE recombination arrives", "description": "Bottom line, Im not worried, but it is interesting\n\nVOCs\n\nWhat is XE?\n\nhttps://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1063424/Tech-Briefing-39-25March2022_FINAL.pdf\n\nhttps://deadline.com/wp-content/uploads/2022/03/20220329_Weekly_Epi_Update_85.pdf\n\nXE strain is a recombinant variant of BA.1 and BA.2 \n\nMutation\n\nAn error is incorporated in the viral genome\n\nRecombination\n\nCoinfecting viruses exchange genetic information, creating a novel virus\n\nChanges to variant classification system \n\nVariant of Concern label\n\na detrimental change in biological properties (changes in transmissibility, severity or immune evasion) compared to the current dominant variant(s); and \n\na growth rate potentially compatible with maintaining transmission and/or displacing the current dominant variant. \n\ndesignate new variants based on genomic features and growth\n\nX = BA.1\nE = BA.2\nX = Delta\nF = Delta\n\nTwo are a combination of Delta and BA.1\n\nXD and XF\n\nXD, few cases detected in France, Belgium, Denmark\n\nXT, small cluster detected in UK, (before 15th Feb)\n\nOne recombination of BA.1 and BA.2\n\nXE is a BA.1/BA.2 recombinant\n\nXE evidence of community transmission within England\ncurrently less than 1% of total sequenced cases\n\nUsing the most recent data up to 16 March 2022\n\nXE has a growth rate 9.8% above that of BA.2\n\nPer week\n\nXE biology\n\n763 XE sequences in the UK data \n\nXE is a BA.1 and BA.2 recombinant\n\n3 mutations that are not present in all BA.1 or BA.2 sequences\n\nBA.2 latest \n\nSGTP is a reasonable proxy for BA.2\n\nEngland on 20 March 2022, 93.7% BA.2\n\nEngland on 6th March 2022, 82.6% BA.2\n\nGrowth rate of BA.2 \n\nIncreased growth rate compared to BA.1 in all regions of England\n\nGrowth rate, 75% greater relative growth for BA.2 compared to BA.1. \n\nGR = 0.753 per week\n\nHospitalisation \n\nNo evidence of a greater risk of hospitalisation following infection with BA.2 compared to BA.1. \n\nSARS-CoV-2 Immunity and Reinfection EvaluatioN (SIREN)\n\n90 day gap\n\nN = 44,000 healthcare workers, recruited from 135 sites\n\nNow highly vaccinated (more than 95%)\n\nTwo weekly PVR testing\n \n\n27th December 2021 to 16th January 2022\n\nN = 496,228 cases of PCR confirmed SARS-CoV-2 infection\n\n186,896 BA.1 confirmed cases with genome sequencing\nThirty-one of these cases had another subsequent sequenced\n\nbut there are no early indications of a specific reinfection issue with this scenario.", "link": "https://www.youtube.com/watch?v=tD-4lNu_k3o", "date_published": "2022-04-03 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}]